A phase I study of adjuvant intensity-modulated radiotherapy with concurrent paclitaxel and cisplatin for cervical cancer patients with high risk factors

2015 ◽  
Vol 32 (11) ◽  
Author(s):  
Pei Shu ◽  
Yali Shen ◽  
Yaqin Zhao ◽  
Feng Xu ◽  
Meng Qiu ◽  
...  
Keyword(s):  
Risk Factors ◽  
Cervical Cancer ◽  
High Risk ◽  
Phase I ◽  
Cancer Patients ◽  
Phase I Study ◽  
Intensity Modulated Radiotherapy ◽  
Intensity Modulated ◽  
High Risk Factors

Post-operative small pelvic intensity-modulated radiation therapy for early-stage cervical cancer with intermediate-risk factors: efficacy and toxicity

2021 ◽  
Author(s):  
Guangyu Zhang ◽  
Fangfang He ◽  
Li Miao ◽  
Haijian Wu ◽  
Youzhong Zhang ◽  
...  
Keyword(s):  
Risk Factors ◽  
Cervical Cancer ◽  
Cancer Patients ◽  
Early Stage ◽  
Intensity Modulated Radiotherapy ◽  
Disease Free Survival ◽  
Intermediate Risk ◽  
Intensity Modulated ◽  
Early Stage Cervical Cancer

Abstract Objective The aim of the present study was to retrospectively evaluate the toxicity and efficacy of post-operative small pelvic intensity-modulated radiotherapy in early-stage cervical cancer patients with intermediate-risk factors. Methods Between 2012 and 2016, 151 patients who had cervical cancer (International Federation of Gynecology and Obstetrics stage I–IIA) with intermediate-risk factors were treated with post-operative small pelvic intensity-modulated radiotherapy. The median dose of 50.4 Gy in 28 fractions with small pelvic intensity-modulated radiotherapy was prescribed to the planning target volume. The intensity-modulated radiotherapy technique used was conventional fixed-field intensity-modulated radiotherapy or helical tomotherapy. Results The median follow-up was 37 months. The 3-year disease-free survival and overall survival rates were 89 and 96%, respectively. A total of 144 patients (95.3%) were alive at the last follow-up. In total, 6 patients (3.9%) had recurrence: locoregional recurrence in 3 patients (2%), distant metastasis in 2 (1.3%), and both in 1 (0.6%). Diarrhoea was the most common acute toxicity. There were no patients suffering from acute or late grade ≥ 3 toxicity. Only 4 patients (2.6%) had late grade 2 toxicities. Conclusions For early-stage cervical cancer patients with intermediate-risk factors, post-operative small pelvic intensity-modulated radiotherapy was safe and well tolerated. The rates of acute and late toxicities were quite satisfactory.

scholarly journals Concurrent chemotherapy and radiotherapy in invasive cervical cancer patients with high risk factors

2000 ◽  
Vol 15 (4) ◽  
pp. 436 ◽  
Author(s):  
Tchan Kyu Park ◽  
Soo Nyung Kim ◽  
Sang Wun Kim ◽  
Gwi Eon Kim ◽  
Chang Ok Suh
Keyword(s):  
Risk Factors ◽  
Cervical Cancer ◽  
High Risk ◽  
Cancer Patients ◽  
Invasive Cervical Cancer ◽  
Concurrent Chemotherapy ◽  
High Risk Factors

scholarly journals Progress of adjuvant therapy after radical resection of early cervical cancer

2020 ◽  
Vol 2 (1) ◽  
Author(s):  
Zhen Zhang
Keyword(s):  
Risk Factors ◽  
Cervical Cancer ◽  
High Risk ◽  
Adjuvant Therapy ◽  
Cancer Patients ◽  
Research Progress ◽  
External Irradiation ◽  
High Risk Factors ◽  
First Choice ◽  
Early Cervical Cancer

Radical surgery is the first choice for the treatment of early cervical cancer. Patients need radiotherapy and chemotherapy according to the risk factors.concurrent chemoradiotherapy with cisplatin is recommended according to NCCN recommended guidelines for the treatment of cervical cancer, with any post-operative high risk factors (lymph node metastasis, positive vaginal margin, and para-uterine infiltration). for cervical cancer patients without high risk factors but with moderate risk factors that meet Sedlis criteria, it is recommended to supplement post-operative pelvic external irradiation ± with concurrent chemotherapy with cisplatin.However, these adjuvant treatments can cause radioactive cystitis and proctitis, even vesicovaginal fistula, rectovaginal fistula, long or irreversible adverse reactions, affecting ovarian function in young patients who retain the ovary, which can lead to a decline in the quality of life of patients. These problems make it a hot topic whether chemotherapy can be used in postoperative adjuvant therapy of cervical cancer patients. This article reviews the research progress of adjuvant therapy for early cervical cancer.

Sign in / Sign up

Export Citation Format

Share Document